Pharmaceutical Technology, January 2023

January 03, 2023

This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.

January 03, 2023

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?

January 03, 2023

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

January 03, 2023

Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.

January 03, 2023

Experts weigh in on trends in the biotechnology market, psychedelics, and India.

January 03, 2023

FDA sent a variety of warning letters to drug manufacturers at the end of 2022 highlighting myriad CGMP and quality control violations.

January 02, 2023

As the therapeutic landscape grows more complex, so too must the analytical techniques for cleaning validation to ensure the utmost cleanliness is achieved.

January 02, 2023

In light of increasingly stringent sustainability requirements, bio/pharma companies need to make sure they formulate effective ESG strategies.

January 02, 2023

CMOs are hoping to grow outsourcing to significantly higher levels in many different areas, with a focus on analytical testing, toxicity testing, and fill/finish operations.

January 02, 2023

Politics and drug shortages will continue to impact FDA and drug manufacturers in 2023.

January 02, 2023

Manufacturers automate production lines and increase the use of third-party providers.

January 02, 2023

Manufacturers must consider key components of manufacturing solid versus semi-solid drugs to create a successful end product.

January 02, 2023

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

January 02, 2023

TreeFrog Therapeutics is leaping ahead in cell therapies through resources such as new technologies and investor partnerships.

January 02, 2023

The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.

January 02, 2023

Does the new regulatory framework have the potential to incentivise R&D investment in rare diseases?

January 02, 2023

A CCS provides significant benefits to the industry and helps with holistically understanding contamination controls, says Siegfried Schmitt, vice president, Technical at Parexel.

January 02, 2023

The ROSS Model HSM-405SC-25 Inline High Shear Mixer with SLIM Technology is a flexible mixing solution.

January 02, 2023

Particle Measuring Systems’ MiniCapt Pro Remote Microbial Air Sampler is designed for effective remote microbial monitoring for cleanroom professionals.

January 02, 2023

Celegance’s Dossplorer can import product registration dossiers and ready regulatory submissions for electronic common technical documents compliance.

January 02, 2023

Bio-Rad Laboratories’ Pioneer Antibody Discovery Platform is an antibody discovery service specifically designed to develop best-in-class biologic candidates.

January 02, 2023

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.